High serum type I interferon (IFN) scores, measured through six chemokines, correlated with poorer lung function and health-related quality of life in patients with diffuse cutaneous systemic ...
The anti-interleukin agent romilkimab showed significant benefits on skin fibrosis among patients with systemic sclerosis in a phase II trial, researchers reported. At week 24, the least squares mean ...
Mycophenolate mofetil (MMF, CellCept) was effective in halting rapidly progressive diffuse cutaneous systemic sclerosis (SSc), but a substantial percentage of patients experienced recurrences when the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results